MyFinsight
Home
Blog
About
Contact
Download
Download image
Impairment of goodwill
$301M
Amortization
$205M
(41.38%↑ Y/Y)
Net income
$187M
(-78.36%↓ Y/Y)
Depreciation
$156M
(18.18%↑ Y/Y)
Other
-$139M
(-379.31%↓ Y/Y)
Other
-$87M
(-112.20%↓ Y/Y)
Accounts receivable
-$79M
(79.37%↑ Y/Y)
Stock-based compensation
$77M
(-26.67%↓ Y/Y)
Deferred income tax
expense (benefit)
$63M
(139.38%↑ Y/Y)
Impairment of assets
$9M
Acquired in-process
research and development...
$6M
(-92.59%↓ Y/Y)
Net cash flows
provided by operating...
$700M
(-25.45%↓ Y/Y)
Effect of exchange rate
changes on cash and cash...
$150M
(297.37%↑ Y/Y)
Canceled cashflow
$609M
Net decrease in cash
and cash...
-$101M
(-461.11%↓ Y/Y)
Canceled cashflow
$850M
Proceeds from debt
$1,055M
(-11.05%↓ Y/Y)
Proceeds from sale of
property, plant and...
$1M
(-75.00%↓ Y/Y)
Trade accounts
payable
-$217M
(-38.22%↓ Y/Y)
Accrued and other
current liabilities
-$142M
(-40.59%↓ Y/Y)
Gain on debt
repurchase
$73M
Income taxes payable
-$61M
(6.15%↑ Y/Y)
Accretion and changes in
fair value in...
$50M
Other current assets
$32M
(-86.44%↓ Y/Y)
Unrealized foreign
exchange (gain) loss
$21M
(950.00%↑ Y/Y)
Inventories
$13M
(-90.08%↓ Y/Y)
Net cash flows used
in financing...
-$561M
(-52.45%↓ Y/Y)
Canceled cashflow
$1,055M
Net cash flows used
in investing...
-$390M
(23.98%↑ Y/Y)
Canceled cashflow
$1M
Repayments of debt
$1,513M
(26.40%↑ Y/Y)
Dividend payments
$88M
(-70.37%↓ Y/Y)
Employee withholding
taxes related to...
$15M
(-31.82%↓ Y/Y)
Capital expenditures
$162M
(-7.43%↓ Y/Y)
Purchase of product
rights and asset...
$124M
(18.10%↑ Y/Y)
Dermavant acquisition,
net of cash acquired
$75M
(-54.82%↓ Y/Y)
Acquired in-process
research and development...
$30M
(-57.75%↓ Y/Y)
Back
Back
Cash Flow
source: myfinsight.com
organon-logo-svg
Organon & Co. (OGN)
organon-logo-svg
Organon & Co. (OGN)